Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Roger M. Lyons, MD, Billie J. Marek, MD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 1350.

https://doi.org/10.1182/blood.V124.21.1350.1350

Published: 2014

Journal Articles

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Matthew M. Heeney, MD FRCP(C), Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD PhD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Elliott Vichinsky, MD, Alex George, MD, PhD

Blood (2014) 124 (21): 4890.

https://doi.org/10.1182/blood.V124.21.4890.4890

Published: 2014

Journal Articles

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito MSHS, McNamara Katie MSHS CCRA, Elliott Vichinsky, MD

Blood (2013) 122 (21): 988.

https://doi.org/10.1182/blood.V122.21.988.988

Published: 2013

Journal Articles

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

Roger M. Lyons, MD, Billie J. Marek, MD, Carole S. Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2775.

https://doi.org/10.1182/blood.V122.21.2775.2775

Published: 2013

Journal Articles

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M. Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito, MSHS, Elliott P. Vichinsky, MD

Blood (2012) 120 (21): 1010.

https://doi.org/10.1182/blood.V120.21.1010.1010

Published: 2012

Journal Articles

Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

Roger M. Lyons, MD, Billie J. Marek, MD, Carole Paley, MD, Jason Esposito, MSHS, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3800.

https://doi.org/10.1182/blood.V120.21.3800.3800

Published: 2012

Journal Articles

24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients

Roger M. Lyons, MD, Billie J. Marek, Surabhi Sharma, Carole Paley, Jason Esposito, Lawrence Garbo, MD, Nicholas DiBella, Guillermo Garcia-Manero

Blood (2011) 118 (21): 2800.

https://doi.org/10.1182/blood.V118.21.2800.2800

Published: 2011

Journal Articles

Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial

Matthew M. Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, Carole Paley, Jason Esposito, Surabhi Sharma, Elliott Vichinsky, MD

Blood (2011) 118 (21): 1060.

https://doi.org/10.1182/blood.V118.21.1060.1060

Published: 2011

Journal Articles

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Stuart L Goldberg, MD, Patricia Giardina, MD, Joan Parkhurst Cain, MD, Deborah Chirnomas, MD, MPH, Jason Esposito, Carole S. Paley, MD, Elliott Vichinsky, MD

Blood (2010) 116 (21): 5155.

https://doi.org/10.1182/blood.V116.21.5155.5155

Published: 2010

Journal Articles

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

Alan F. List, Maria R. Baer, David P. Steensma, Azra Raza, Jason Esposito, Noelia Martinez-Lopez, Carole Paley, John Feigert, Emmanuel C. Besa

Blood (2009) 114 (22): 3829.

https://doi.org/10.1182/blood.V114.22.3829.3829

Published: 2009

Journal Articles

Iron Chelation with Deferasirox (Exjade ® ) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Alan F List, Maria R Baer, David Steensma, Azra Raza, Jason Esposito, Jodi Virkus, Carole Paley, John Feigert, Emmanuel C Besa

Blood (2008) 112 (11): 634.

https://doi.org/10.1182/blood.V112.11.634.634

Published: 2008

Journal Articles

Iron Parameters in 84 MDS Patients Enrolled in a Deferasirox (Exjade®, ICL670) Multicenter Trial.

Alan F. List, Jason Esposito, Jodie Decker, Maria R. Baer, Bayard Powell, David Steensma, Azra Raza, Howard Terebelo, Jaroslaw Maciejewski, Stuart L. Goldberg, Carole Paley

Blood (2006) 108 (11): 4847.

https://doi.org/10.1182/blood.V108.11.4847.4847

Published: 2006

NARROW

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients

Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

Iron Chelation with Deferasirox (Exjade ® ) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Iron Parameters in 84 MDS Patients Enrolled in a Deferasirox (Exjade®, ICL670) Multicenter Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only